Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Trospective Comparison Focusing on Pulmonary Toxicity.
Romana WassMaximilian Johannes HochmairBernhard KaiserBrane GrambozovPetra FeursteinGertraud WeißRaphaela MoosbruggerFelix SedlmayerBernd LamprechtMichael StudnickaFranz ZehentmayrPublished in: Cancers (2022)
The data of this hypothesis-generating study suggest that sequential high-dose chemoradiation followed by durvalumab might be similar to SoC in terms of pulmonary toxicity and potentially more effective with respect to intra-thoracic disease control. Larger trials with a prospective design are warranted to validate these results.
Keyphrases
- high dose
- pulmonary hypertension
- rectal cancer
- low dose
- stem cell transplantation
- locally advanced
- oxidative stress
- small cell lung cancer
- healthcare
- palliative care
- spinal cord
- squamous cell carcinoma
- electronic health record
- quality improvement
- advanced non small cell lung cancer
- big data
- spinal cord injury
- machine learning
- radiation therapy
- pain management
- health insurance
- artificial intelligence
- chronic pain
- clinical evaluation